View Older Stories View More Recent Stories

Aug 1, 2019 04:05PM Emergent BioSolutions Reports Financial Results for Second Quarter and Six Months Ended June 30, 2019
Jul 30, 2019 04:42PM Emergent BioSolutions Announces Exercise by BARDA of the First Contract Option, Valued at $261 Million, to Procure Doses of AV7909 Anthrax Vaccine Candidate for the Strategic National Stockpile
Jul 30, 2019 04:42PM Emergent BioSolutions Announces Exercise by BARDA of the First Contract Option, Valued at $261 Million, to Procure Doses of AV7909 Anthrax Vaccine Candidate for the Strategic National Stockpile
Jul 18, 2019 06:30AM Emergent BioSolutions to Release Second Quarter 2019 Financial Results and Conduct a Conference Call on August 1, 2019
Jul 18, 2019 06:30AM Emergent BioSolutions to Release Second Quarter 2019 Financial Results and Conduct a Conference Call on August 1, 2019
Jun 4, 2019 04:08PM Emergent BioSolutions (EBS) Announces FDA Approval of Change in Storage Conditions and Transfer of Manufacturing for Its Cholera Vaccine
Jun 4, 2019 04:05PM Emergent BioSolutions Announces FDA Approval of Change in Storage Conditions and Transfer of Manufacturing for Its Cholera Vaccine
Jun 4, 2019 04:05PM Emergent BioSolutions Announces FDA Approval of Change in Storage Conditions and Transfer of Manufacturing for Its Cholera Vaccine
Jun 3, 2019 06:33AM Emergent BioSolutions (EBS) Secures 10-Yr HHS Contract Valued at $35M to Vaccinia Immune Globulin Intravenous in Support of Smallpox Preparedness
Jun 3, 2019 06:30AM Emergent BioSolutions Awarded 10-Year HHS Contract Valued at Approximately $535 Million to Deliver Vaccinia Immune Globulin Intravenous (VIGIV) in Support of Smallpox Preparedness
Jun 3, 2019 06:30AM Emergent BioSolutions Awarded 10-Year HHS Contract Valued at Approximately $535 Million to Deliver Vaccinia Immune Globulin Intravenous (VIGIV) in Support of Smallpox Preparedness
May 20, 2019 06:30AM Emergent BioSolutions to Participate in Series of Investor Conferences
May 20, 2019 06:30AM Emergent BioSolutions to Participate in Series of Investor Conferences
May 15, 2019 04:05PM Emergent BioSolutions Prepares for Initial Shipments of AV7909 Anthrax Vaccine Candidate into the Strategic National Stockpile
May 15, 2019 04:05PM Emergent BioSolutions Prepares for Initial Shipments of AV7909 Anthrax Vaccine Candidate into the Strategic National Stockpile
May 9, 2019 06:30AM Emergent BioSolutions to Hold Annual Meeting of Stockholders on Thursday, May 23, 2019 at 9:00 AM EDT; Webcast Will Be Available
May 9, 2019 06:30AM Emergent BioSolutions to Hold Annual Meeting of Stockholders on Thursday, May 23, 2019 at 9:00 AM EDT; Webcast Will Be Available
May 2, 2019 04:05PM Emergent BioSolutions Reports First Quarter 2019 Financial Results
May 2, 2019 04:05PM Emergent BioSolutions Reports First Quarter 2019 Financial Results
Apr 18, 2019 07:22AM Emergent BioSolutions to Release First Quarter 2019 Financial Results and Conduct a Conference Call on May 2, 2019
Apr 18, 2019 07:22AM Emergent BioSolutions to Release First Quarter 2019 Financial Results and Conduct a Conference Call on May 2, 2019
Apr 16, 2019 06:33AM Emergent BioSolutions (EBS) Announces Positive Phase 2 Study Evaluating Chikungunya Virus Treatment CHIKV-VLP
Apr 16, 2019 06:30AM Emergent BioSolutions Announces Interim Results From Phase 2 Study Evaluating CHIKV-VLP, Chikungunya Virus Vaccine Candidate
Apr 16, 2019 06:30AM Emergent BioSolutions Announces Interim Results From Phase 2 Study Evaluating CHIKV-VLP, Chikungunya Virus Vaccine Candidate
Mar 19, 2019 06:31AM Emergent BioSolutions (EBS) Initiates Phase 3 Clinical Study to Evaluate AV7909 for Post-Exposure Prophylaxis of Anthrax
Mar 19, 2019 06:30AM Emergent BioSolutions Initiates Phase 3 Clinical Study to Evaluate AV7909 for Post-Exposure Prophylaxis of Anthrax
Mar 19, 2019 06:30AM Emergent BioSolutions Initiates Phase 3 Clinical Study to Evaluate AV7909 for Post-Exposure Prophylaxis of Anthrax
Feb 28, 2019 04:45PM Emergent BioSolutions Awarded U.S. Department of State Contract to Supply Medical Countermeasures For Chemical Warfare Agents
Feb 28, 2019 04:45PM Emergent BioSolutions Awarded U.S. Department of State Contract to Supply Medical Countermeasures For Chemical Warfare Agents
Feb 21, 2019 04:05PM Emergent BioSolutions Reports Fourth Quarter and Full Year 2018 Financial Results
Feb 21, 2019 04:05PM Emergent BioSolutions Reports Fourth Quarter and Full Year 2018 Financial Results
Feb 12, 2019 06:34AM Emergent BioSolutions (EBS) Appoints Seamus Mulligan to Board
Feb 12, 2019 06:30AM Emergent BioSolutions Announces Appointment of Seamus Mulligan to its Board of Directors
Feb 12, 2019 06:30AM Emergent BioSolutions Announces Appointment of Seamus Mulligan to its Board of Directors
Feb 7, 2019 09:35AM Emergent BioSolutions to Release Fourth Quarter and Full Year 2018 Financial Results and Conduct a Conference Call on February 21, 2019
Feb 7, 2019 09:35AM Emergent BioSolutions to Release Fourth Quarter and Full Year 2018 Financial Results and Conduct a Conference Call on February 21, 2019
Jan 24, 2019 07:04AM Emergent BioSolutions (EBS) Appoints Robert G. Kramer, Sr. to Board
Jan 24, 2019 07:00AM Emergent BioSolutions Announces Appointment of Robert G. Kramer, Sr. to Its Board of Directors
Jan 24, 2019 07:00AM Emergent BioSolutions Announces Appointment of Robert G. Kramer, Sr. to Its Board of Directors
Jan 7, 2019 06:33AM Emergent BioSolutions (EBS) Reports Prelim. FY18 Revenues Above Consensus; Offers FY19 Revenue Guidance Above Consensus
Jan 7, 2019 06:30AM Emergent BioSolutions Announces Preliminary 2018 Financial Results and Provides 2019 Financial Forecast
Jan 7, 2019 06:30AM Emergent BioSolutions Announces Preliminary 2018 Financial Results and Provides 2019 Financial Forecast
Jan 4, 2019 07:02AM Emergent BioSolutions (EBS) Reports Robert G. Kramer to Become New President & CEO, Following Retirement of CEO Daniel J. Abdun-Nabi
Jan 4, 2019 07:00AM Emergent BioSolutions Announces Daniel J. Abdun-Nabi to Retire as CEO; Robert G. Kramer, Sr. to Become President and CEO
Jan 4, 2019 07:00AM Emergent BioSolutions Announces Daniel J. Abdun-Nabi to Retire as CEO; Robert G. Kramer, Sr. to Become President and CEO
Dec 28, 2018 09:02AM Emergent BioSolutions (EBS) Submits Application Covering Emergency Use Authorization for NuThrax to FDA
Dec 28, 2018 09:01AM Emergent BioSolutions Announces Submission to FDA of Application Covering Emergency Use Authorization for NuThrax™
Dec 28, 2018 09:01AM Emergent BioSolutions Announces Submission to FDA of Application Covering Emergency Use Authorization for NuThrax™
Dec 17, 2018 04:11PM Emergent BioSolutions (EBS) Granted Health Canada Approval of BioThrax (Anthrax Vaccine Adsorbed)
Dec 17, 2018 04:10PM Emergent BioSolutions Receives Health Canada Approval of BioThrax® (Anthrax Vaccine Adsorbed)
View More Recent Stories View Older Stories